菜单
CRO Services

Drug Development Expertise Empowering Research Services for Biologics


Speak with our Experts

In Vivo Pharmacology Services

Science-Driven PK/PD, Efficacy, Toxicology Studies via Multi-Species Platforms

WuXi Biologics CRO Services provides multi-species in vivo pharmacology services covering PK/PD, efficacy, toxicology, and immunohistology studies. With extensive experience across 900+ NHP studies annually and support for diverse modalities including mAbs, bsAbs, multispecific antibodies, and ADCs, our in vivo study platform helps advance projects across oncology, autoimmune, and metabolic diseases toward preclinical research and clinical development.

CORE STRENGTH

In Vivo Pharmacology Service Highlights

Zero Lead Time for NHP Scheduling

Seamless transition from gram-scale production to NHP PK/PD studies without animal scheduling delays.

Multi-Species Translational Platform

Support mouse, rat, and NHP in vivo testing with total timelines of 6–11 weeks.

Comprehensive PK/PD and Toxicology Studies

Assess exposure–response relationships, target engagement, and early safety signals.

200+ Validated In Vivo Models

165 efficacy models spanning syngeneic, CDX/PBMC, and IVIS platforms, plus 36 autoimmune and metabolic disease models.


~ 400

NHP naïve & non-naïve projects annually

~ 500

Mouse studies delivered annually

200+

Validated efficacy models
Service Details

Detailed In Vivo Pharmacology Services

Our science-driven in vivo pharmacology platform supports PK/PD, efficacy, toxicology, and immunohistology studies with rational design, multi-species capabilities, and decision-ready data for preclinical and translational development.

01

Pharmacokinetics and Pharmacodynamics (PK/PD)

↔ Flip for details

  • PK Studies: Serum/plasma concentration of total IgG, total antibody, total ADC, or free payload; analyze half-life, clearance, AUC, etc.
  • PD Studies: Immunophenotyping and receptor occupancy analysis
02

Efficacy Models

↔ Flip for details

  • 200+ in vivo models: Cover oncology (syngeneic, CDX/PBMC, and IVIS imaging), autoimmune and metabolic disease models
  • Extensive expertise with bispecifics/TCEs, ADCs, and complex formats
  • Fit-for-purpose study design, model selection, and data interpretation
03

Toxicology Studies

↔ Flip for details

  • Safety Readouts: Cytokine analysis and CHEM/HEM, urine, and coagulation testing
  • Clinical Observations: Survival curve, body weight curve, and general clinical signs
  • Necropsy Analysis: Necropsy report and organ weight assessment
04

Immunohistology

↔ Flip for details

  • Histology: Slides and raw staining images with pathological diagnosis of tissue morphology and immune cell infiltration
  • IHC/IF: Slides and raw staining images with quantifiable analysis for antibody distribution and target validation

 

Case Studies

Science-Driven In Vivo Pharmacology for PK/PD, Efficacy, and Toxicology Studies

Case Study 1: Comprehensive In Vivo PK/PD and Toxicology Studies for TCEs

This case study highlights comprehensive in vivo PK/PD/toxicology studies for bispecific T cell engagers (TCEs). The study integrated pharmacokinetics and pharmacodynamics assessments such as tissue biodistribution, immunophenotyping, and receptor occupancy, together with toxicology testing including cytokine monitoring, hematology, and immunohistochemical staining to support TCE in vivo preclinical studies.

Comprehensive in vivo PK/PD and toxicology assessment for TCEs

Case Study 2: CDX/PBMC Humanized In Vivo Efficacy Model for TCEs +

This case study highlights a CDX/PBMC in vivo mouse model for TCE efficacy studies. Severely immune-deficient mice were reconstituted with human PBMCs before CDX tumor cell inoculation, enabling target validation and in vivo assessment of dose-dependent anti-tumor activity for preclinical studies.

CDX/PBMC humanized in vivo mouse model for TCE efficacy

Case Study 3: Immunohistology Enables Tumor Model Selection and Immune Profiling +

This case study demonstrates how immunohistochemistry (IHC) and immunofluorescence (IF) staining support comprehensive tissue-level analysis for in vivo studies in drug discovery. Tumor antigen IHC guided model selection, Fc IHC confirmed ADC tissue distribution, CD4 IHC identified T cell infiltration, and multiplex IF enabled broader immune profiling.

Immunohistology-based tumor model selection and immune profiling

Why WuXi Biologics

Why Work with WuXi Biologics for In Vivo Pharmacology Studies

  • Science-Driven Multi-Species Support: Access mouse, rat, and NHP studies across PK/PD, toxicology, and efficacy studies.
  • Zero Lead Time for NHP Scheduling: Move seamlessly from gram-scale protein production to NHP PK/PD studies without scheduling delays.
  • Broad Modality Experience: Support mAbs, bsAbs, multispecific antibodies, ADCs, fusion proteins, and CAR-T therapies.
  • Translational Study Design: Backed by extensive drug development expertise, rational study design, and strategic model selection to support preclinical decisions.
Get Started

Rational In Vivo Studies for Translational Insights

Advance your drug discovery projects with WuXi Biologics’ science-driven in vivo studies. From PK/PD and efficacy models to ADA, non-GLP toxicology studies, and immunohistology, we help generate decision-ready, translational data across diverse in vivo models and key therapeutic areas to support a smoother path from preclinical research to clinical development.